Goodbye allergic asthma?

Every spring, the same battle: allergic asthma poisons the lives of millions of people.

This form of asthma, triggered by allergens such as pollen, dust mites or animal hair, accounts for around 50% of asthma cases worldwide.

As well as causing respiratory discomfort, it has a lasting impact on quality of life, and remains difficult to control, particularly in its severe forms.

Today, the treatments available - inhaled corticosteroids or monoclonal antibodies - are effective, but cumbersome, costly and restrictive over the long term.

Faced with this public health challenge, Institut Pasteur researchers, led by Pierre Bruhns, are working to better understand the mechanisms of this disease and develop new therapeutic approaches.

Among them, a vaccine is currently being evaluated in partnership with Inserm Transfert and NEOVACS, and initial experimental results offer promising prospects for the years to come.

A concrete hope for living better with allergic asthma.

(video in french, English subtitles available)